Clinical Trial Update: A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the pharmacokinetics and safety of pemafibrate (K-808) in subjects with primary biliary cholangitis with compensated cirrhosis and with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis
• Cirrhosis

Drugs mentioned

• Pemafibrate (pemafibrate)

Snippet

Sponsor: Kowa Research Institute, Inc. | Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis | Phase 1 | Status: COMPLETED